SF3B1 and myelodysplastic syndrome: Of the remaining cases having SF3B1 mutations with VAFs <15% (n = 13), 5/13 (39%) samples were MDS 5q-, 6 (46%) MDS-EB-1/2 and 2 (15%) were SF3B1ent (Fig. 3B).